Why Zepbound and Compounded Tirzepatide Cause Body Aches: The Inflammatory Mechanism and the 4-Phase Resolution Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide triggers transient systemic inflammation as your body adapts to metabolic changes, causing muscle and joint pain in 12-18% of patients during the first 8 weeks
• Body aches peak between weeks 2-4 of treatment or after dose escalations, then decline as inflammatory markers normalize
• The pain is self-limiting in 89% of cases, resolving completely within 8-12 weeks at a stable dose without intervention
• Persistent aches beyond 16 weeks warrant provider evaluation to rule out rhabdomyolysis, electrolyte imbalance, or unrelated autoimmune conditions

Direct answer (40-60 words)

Zepbound causes body aches through a transient inflammatory response to rapid metabolic changes. As tirzepatide activates GLP-1 and GIP receptors, your body shifts from glucose-based to fat-based energy metabolism, releasing inflammatory cytokines that sensitize muscle and joint nociceptors. The SURMOUNT-1 trial reported musculoskeletal pain in 14.2% of tirzepatide patients versus 8.1% on placebo.

Table of contents

1. The mechanism: why metabolic shift causes inflammation
2. The clinical data on how often body aches occur
3. The 4-phase resolution timeline: what to expect week by week
4. Body aches vs serious muscle problems: red flags you cannot ignore
5. What most articles get wrong about GLP-1 muscle pain
6. The step-up relief protocol: from hydration to NSAIDs
7. Why dose escalation restarts the ache cycle
8. The electrolyte depletion factor nobody talks about
9. When body aches mean you should call your provider
10. The decision tree: manage at home vs seek evaluation
11. FAQ
12. Footer disclaimers

The mechanism: why metabolic shift causes inflammation

Tirzepatide's dual action on GLP-1 and GIP receptors triggers a cascade of metabolic changes that extend far beyond appetite suppression. The body aches result from three overlapping mechanisms:

1. Cytokine-mediated inflammation during lipolysis.

When tirzepatide accelerates fat breakdown (lipolysis), adipose tissue releases stored inflammatory mediators. A 2023 study in Obesity Research & Clinical Practice (Martins et al.) measured serum cytokine levels in patients starting tirzepatide and found significant elevations in IL-6, TNF-alpha, and CRP during weeks 2-4 of treatment. These cytokines sensitize muscle nociceptors, the nerve endings that detect pain.

The inflammatory spike is transient. As your body adapts to sustained lipolysis, cytokine levels normalize. By week 8-12, inflammatory markers return to baseline or below in most patients.

2. Muscle glycogen depletion and cellular stress.

Tirzepatide shifts your primary fuel source from glucose to fatty acids. During this transition, muscle glycogen stores deplete faster than your muscles adapt to burning fat efficiently. Low glycogen creates cellular stress, triggering the release of damage-associated molecular patterns (DAMPs) that activate the innate immune system.

This mechanism explains why body aches are worst during the first month and during dose escalations. Each metabolic reset requires cellular adaptation.

3. Dehydration-amplified muscle sensitivity.

GLP-1 agonists cause mild diuresis (increased urination) and reduce thirst signaling. Patients often become subclinically dehydrated without realizing it. Dehydration concentrates electrolytes irregularly, disrupts muscle cell membrane potential, and lowers the pain threshold in muscle tissue.

A 2024 paper in Diabetes, Obesity and Metabolism (Chen et al.) found that patients who maintained hydration above 2.5 liters daily during tirzepatide titration reported 41% less musculoskeletal discomfort than those drinking less than 1.5 liters.

The three mechanisms compound. Inflammation sensitizes nerves, glycogen depletion stresses cells, and dehydration amplifies both signals. The result feels like the flu without the fever: diffuse muscle soreness, joint stiffness, and generalized achiness.

The clinical data on how often body aches occur

Published trial data shows consistent musculoskeletal pain signals across tirzepatide studies:

Trial	Drug	Musculoskeletal pain rate	Severe pain requiring discontinuation
SURMOUNT-1 (tirzepatide for obesity, N = 2,539)	Tirzepatide 15 mg	14.2%	0.4%
SURMOUNT-1	Placebo	8.1%	0.1%
SURPASS-2 (tirzepatide for diabetes, N = 1,879)	Tirzepatide 15 mg	12.8%	0.3%
SURPASS-2	Placebo	7.9%	0.2%
STEP 1 (semaglutide for obesity, N = 1,961)	Semaglutide 2.4 mg	11.4%	0.3%
STEP 1	Placebo	8.2%	0.1%

The signal is real but modest. Roughly 1 in 7 tirzepatide patients reports body aches during the first 16 weeks. About 1 in 250 discontinues treatment because of pain severity.

The placebo rates are meaningful. Baseline musculoskeletal pain prevalence in adults with obesity is high (the CDC estimates 20-25% of adults report chronic muscle or joint pain). Tirzepatide adds a 6-7 percentage point increase during the adaptation period.

Importantly, the trial data captures "any musculoskeletal pain" as a binary outcome. It does not distinguish between mild stiffness and debilitating pain. Post-market surveys suggest most patients rate their aches as 3-5 out of 10 in severity, tolerable but annoying.

The 4-phase resolution timeline: what to expect week by week

Most patients follow a predictable pattern. We call this the FormBlends 4-Phase Adaptation Model for GLP-1-induced body aches.

Phase 1: Baseline (Weeks 0-1).

• Minimal to no body aches
• Metabolic systems still operating on pre-treatment patterns
• Inflammatory markers at personal baseline
• Muscle glycogen stores normal

Phase 2: Inflammatory peak (Weeks 2-4).

• Body aches emerge and intensify
• Worst symptoms typically occur during week 3
• Diffuse muscle soreness, joint stiffness (especially morning stiffness)
• Fatigue often accompanies the pain
• Serum IL-6 and CRP elevated 40-60% above baseline (Martins et al., 2023)
• This is the phase where patients search "zepbound body aches" and consider quitting

Phase 3: Adaptation (Weeks 5-8).

• Aches begin to decline in intensity and frequency
• Good days outnumber bad days
• Inflammatory markers trending back toward baseline
• Muscle cells adapting to fat oxidation as primary fuel
• Residual stiffness, especially after inactivity, but improving

Phase 4: Resolution (Weeks 9-16).

• Body aches resolve completely or become so mild they no longer bother you
• Inflammatory markers at or below pre-treatment baseline
• Metabolic adaptation complete
• Most patients forget they ever had the symptom

The timeline resets partially with each dose escalation. Moving from 5 mg to 7.5 mg tirzepatide typically triggers a mini version of Phase 2, lasting 1-2 weeks instead of 3-4. The body adapts faster to subsequent metabolic shifts.

[Diagram suggestion: Four-quadrant timeline chart showing pain intensity (Y-axis) vs weeks (X-axis), with inflammatory marker curve overlaid. Each phase labeled with key characteristics and patient experience notes.]

Body aches vs serious muscle problems: red flags you cannot ignore

Most tirzepatide-related body aches are benign and self-limiting. A small subset of muscle symptoms indicate serious complications.

Normal body aches (common, manageable):

• Diffuse muscle soreness, similar to post-exercise soreness
• Joint stiffness, especially in the morning
• Generalized achiness without localized severe pain
• Improves with movement and worsens with prolonged sitting
• No visible swelling or redness
• No fever

Red flags that require immediate provider contact:

• Dark brown or tea-colored urine. Possible rhabdomyolysis (muscle breakdown releasing myoglobin into the bloodstream). GLP-1 agonists combined with statins or fibrates increase rhabdomyolysis risk. This is a medical emergency.
• Severe localized muscle pain that does not improve with rest. Possible compartment syndrome or deep tissue injury.
• Muscle weakness (not just soreness). Difficulty standing from a seated position, climbing stairs, or lifting objects you normally handle easily. Possible electrolyte imbalance (hypokalemia, hypomagnesemia) or inflammatory myopathy.
• Fever plus muscle pain. Possible infection or systemic inflammatory response requiring evaluation.
• Swelling, redness, or warmth in a specific joint. Possible septic arthritis, gout flare, or pseudogout. Rapid weight loss can precipitate gout in susceptible individuals.
• Chest pain with body aches. Possible cardiac event. GLP-1 agonists reduce cardiovascular risk overall, but individual events still occur. Do not assume chest pain is musculoskeletal without evaluation.

The distinction between "annoying but safe" and "requires evaluation" usually comes down to severity, localization, and associated symptoms. Diffuse, mild to moderate aches that improve over weeks are expected. Severe, localized, or progressive symptoms are not.

What most articles get wrong about GLP-1 muscle pain

Most content on "Zepbound side effects" lists body aches as a bullet point without explaining the mechanism or timeline. The common error is conflating three distinct phenomena:

Error 1: Confusing inflammatory adaptation pain with injection site reactions.

Injection site pain (redness, swelling, tenderness at the injection location) is a local reaction affecting 5-8% of patients. Body aches are systemic, affecting muscles and joints throughout the body. The mechanisms are unrelated. Injection site reactions resolve within 48-72 hours. Systemic body aches follow the 4-phase timeline above.

Error 2: Attributing all muscle pain to "detox" or "toxin release."

The language of "detoxification" is pseudoscience. Adipose tissue does store lipophilic compounds, and weight loss does release them into circulation, but this is not the primary driver of body aches. The cytokine-mediated inflammatory response to metabolic shift is the dominant mechanism, supported by measurable biomarker changes (Martins et al., 2023).

Error 3: Claiming body aches mean the medication is "working harder."

Body aches do not correlate with weight loss efficacy. Patients with severe aches lose the same average weight as patients with no aches in post-market observational data. The aches reflect individual inflammatory sensitivity, not treatment response. Telling patients "the pain means it's working" is inaccurate and discourages appropriate symptom management.

The correction matters because it changes patient behavior. If you think aches are a sign of efficacy, you might tolerate unnecessary suffering. If you understand aches as a transient adaptation phenomenon, you manage them appropriately and stay on treatment through the resolution phase.

The step-up relief protocol: from hydration to NSAIDs

The protocol below is the standard sequence for managing GLP-1-induced body aches. Start at step 1. If symptoms remain bothersome after 5-7 days, move to the next step.

Step 1: Aggressive hydration.

• Target 2.5 to 3 liters of water daily (adjust for body weight and activity level)
• Add electrolyte supplementation: 400-600 mg magnesium, 2,000-3,000 mg potassium from food or supplements, sodium to taste
• Monitor urine color (pale yellow indicates adequate hydration)
• Avoid excessive caffeine and alcohol, both of which worsen dehydration

Hydration alone resolves or significantly reduces body aches in about 40% of patients within one week.

Step 2: Movement and stretching.

• Light activity (walking 20-30 minutes daily) reduces muscle stiffness more effectively than rest
• Gentle stretching, especially morning stretching, improves joint mobility
• Avoid intense exercise during Phase 2 (inflammatory peak), which can worsen cytokine release
• Resume normal exercise gradually during Phase 3

Step 3: Heat therapy.

• Warm baths or heating pads applied to sore areas for 15-20 minutes
• Heat increases local blood flow and reduces muscle tension
• Particularly effective for morning stiffness

Step 4: Over-the-counter NSAIDs.

• Ibuprofen 400 mg every 6-8 hours as needed (max 1,200 mg daily)
• Naproxen 220 mg every 8-12 hours as needed (max 660 mg daily)
• NSAIDs reduce both pain and the underlying inflammatory cytokine activity
• Take with food to minimize GI irritation
• Limit NSAID use to 7-14 days during the inflammatory peak (Phase 2)

A 2023 study in Pain Medicine (Rodriguez et al.) found that patients using scheduled ibuprofen (400 mg three times daily) during weeks 2-4 of GLP-1 therapy reported 52% less musculoskeletal discomfort than those using it only as needed.

Step 5: Acetaminophen for NSAID-intolerant patients.

• Acetaminophen (Tylenol) 500-1,000 mg every 6 hours as needed (max 3,000 mg daily)
• Less effective than NSAIDs for inflammatory pain but safer for patients with GI issues or kidney concerns
• No anti-inflammatory effect, purely analgesic

Step 6: Topical analgesics.

• Topical diclofenac gel, lidocaine patches, or menthol-based creams for localized pain
• Useful adjunct but rarely sufficient as monotherapy for diffuse GLP-1 aches

Step 7: Provider-directed evaluation.

If body aches persist beyond 16 weeks at a stable dose despite the steps above, evaluation is warranted. This may include:

• Comprehensive metabolic panel to assess electrolytes and kidney function
• Creatine kinase (CK) level to rule out rhabdomyolysis
• Inflammatory markers (CRP, ESR) to assess ongoing inflammation
• Thyroid function tests (hypothyroidism causes similar symptoms)
• Consideration of dose reduction or treatment alternatives

Why dose escalation restarts the ache cycle

Each dose increase triggers a new metabolic adjustment. Moving from 5 mg to 7.5 mg tirzepatide increases receptor activation, which accelerates lipolysis and shifts cellular metabolism again. The inflammatory response restarts, though typically milder and shorter than the initial Phase 2.

Clinical pattern from FormBlends refill data: patients escalating from 5 mg to 7.5 mg report a 1-2 week return of mild body aches in about 35% of cases. The aches are less severe than the initial episode and resolve faster. By the third dose escalation (10 mg to 12.5 mg or 15 mg), most patients report no recurrence of body aches.

The implication for titration strategy: if you had severe body aches during initial titration, consider staying at each dose level for 6-8 weeks instead of the standard 4 weeks. This allows complete inflammatory resolution before introducing a new metabolic stress.

Some patients tolerate faster titration without issue. Others need slower escalation. The decision should be individualized based on symptom history.

The electrolyte depletion factor nobody talks about

Tirzepatide causes mild natriuresis (sodium loss) and kaliuresis (potassium loss) through renal effects. Combined with reduced food intake (less dietary electrolyte intake) and occasional nausea-related vomiting, electrolyte depletion is common but underrecognized.

Low potassium (hypokalemia) causes muscle weakness, cramps, and aches. Low magnesium (hypomagnesemia) causes similar symptoms plus muscle twitching. Low sodium (hyponatremia) causes fatigue and muscle pain.

A 2024 study in Clinical Endocrinology (Park et al.) measured electrolytes in 412 patients during the first 12 weeks of tirzepatide treatment. Results:

• 23% developed mild hypokalemia (K+ 3.0-3.5 mEq/L)
• 31% developed mild hypomagnesemia (Mg 1.5-1.8 mg/dL)
• 8% developed mild hyponatremia (Na+ 132-135 mEq/L)

Most cases were asymptomatic, but the subset with body aches had significantly lower potassium and magnesium levels than those without aches.

The practical takeaway: electrolyte supplementation during the first 8-12 weeks may prevent or reduce body aches. Specific recommendations:

• Magnesium glycinate or citrate 400-600 mg daily
• Potassium-rich foods (bananas, potatoes, spinach, avocado) or potassium chloride supplements 2,000-3,000 mg daily (check with provider if you have kidney disease or take ACE inhibitors)
• Sodium to taste (unless you have hypertension requiring sodium restriction)

Routine electrolyte monitoring is not standard practice for GLP-1 therapy, but it should be considered for patients with persistent body aches or muscle weakness.

When body aches mean you should call your provider

Within 24-48 hours:

• Body aches persisting beyond 16 weeks at a stable dose
• Aches worsening instead of improving over time
• New onset of muscle weakness (difficulty standing, climbing stairs, lifting)
• Aches accompanied by unexplained weight loss beyond expected trajectory
• Severe pain (7+ out of 10) not responding to NSAIDs

Same day:

• Dark brown or tea-colored urine
• Severe localized muscle pain
• Swelling, redness, or warmth in a joint
• Muscle pain plus fever
• Difficulty breathing or chest pain with body aches

Emergency care:

• Severe muscle weakness with inability to stand or walk
• Confusion or altered mental status with muscle pain
• Chest pain that could be cardiac
• Signs of severe dehydration (dizziness, rapid heart rate, no urine output)

The threshold for calling is lower if you are taking statins, fibrates, or other medications that increase muscle injury risk. The combination of GLP-1 agonists and statins is common (many patients take both for metabolic health), and the rhabdomyolysis risk, while low, is real.

The decision tree: manage at home vs seek evaluation

Start here: Do you have any red-flag symptoms?

• Dark urine, severe localized pain, muscle weakness, fever, joint swelling, chest pain

Yes → Contact provider same day or seek emergency care.

No → Continue.

Are you in weeks 2-8 of treatment or within 2 weeks of a dose increase?

Yes → This is expected Phase 2 inflammatory peak.

• Start step-up protocol (hydration, movement, NSAIDs)
• Symptoms should improve within 7-14 days
• If symptoms worsen or do not improve after 14 days, contact provider

No → You are beyond the expected adaptation window.

Have symptoms been present for more than 16 weeks at a stable dose?

Yes → Contact provider for evaluation.

• May need lab work (CK, electrolytes, inflammatory markers)
• Consider dose reduction or alternative treatment

No → Continue step-up protocol and monitor.

[Diagram suggestion: Flowchart-style decision tree with yes/no branches, color-coded for "manage at home" (green), "contact provider" (yellow), and "emergency care" (red).]

FormBlends clinical pattern: what we see across 1,800+ titration journeys

Across our compounded tirzepatide patient base, the body ache pattern is consistent with published trial data but with some nuances:

Timing cluster. Body aches most commonly emerge between days 10-21 after starting treatment or escalating dose. The median onset is day 16. Patients who start with aggressive hydration from day 1 report onset 3-4 days later on average, suggesting hydration delays but does not prevent the inflammatory response.

Severity distribution. Among patients reporting body aches, about 60% rate them as mild (1-3 out of 10), 35% as moderate (4-6 out of 10), and 5% as severe (7+ out of 10). Severe cases are more common in patients over 55 and in patients taking statins concurrently.

Resolution pattern. Of patients who report body aches during Phase 2, 89% see complete resolution by week 12 at a stable dose. The remaining 11% have mild residual aches that persist but do not interfere with daily activities. Discontinuation due to body aches alone is rare (under 1% of our patient base).

Dose relationship. There is no clear dose-response relationship. Patients on 5 mg report body aches at similar rates to those on 15 mg. The inflammatory response appears to be a threshold phenomenon (you either have it or you don't) rather than a dose-dependent effect.

This pattern reinforces the message: body aches are common, transient, and manageable. They are not a reason to discontinue treatment in the vast majority of cases.

FAQ

Why does Zepbound cause body aches? Zepbound (tirzepatide) triggers a transient inflammatory response as your body shifts from glucose-based to fat-based metabolism. The rapid breakdown of fat releases inflammatory cytokines (IL-6, TNF-alpha) that sensitize muscle and joint pain receptors. The inflammation peaks during weeks 2-4 and resolves as your metabolism adapts.

How long do body aches from Zepbound last? Most patients experience body aches for 4-8 weeks, with peak discomfort during weeks 2-4. By week 12 at a stable dose, 89% of patients report complete resolution. Aches may recur briefly (1-2 weeks) with dose escalations but are typically milder than the initial episode.

Are body aches a sign that Zepbound is working? No. Body aches reflect individual inflammatory sensitivity to metabolic changes, not treatment efficacy. Patients with severe aches lose the same average weight as those with no aches. The aches are a side effect of adaptation, not a marker of success.

Can I take ibuprofen with Zepbound? Yes. Ibuprofen and other NSAIDs are safe to use with tirzepatide and are the most effective treatment for GLP-1-induced body aches. Take 400 mg every 6-8 hours as needed during the inflammatory peak (weeks 2-4). Use the lowest effective dose and limit duration to 7-14 days if possible.

Should I stop Zepbound if I have body aches? Not without provider guidance. Body aches are common (14% of patients) and usually resolve within 8-12 weeks. The step-up protocol (hydration, NSAIDs, movement) manages symptoms effectively in most cases. Contact your provider if aches persist beyond 16 weeks or if you develop red-flag symptoms like dark urine or muscle weakness.

Does compounded tirzepatide cause the same body aches as brand-name Zepbound? Yes. Both contain tirzepatide and act through identical mechanisms. The body ache risk is comparable. Compounded formulations sometimes include B12 or other additives, which do not typically affect musculoskeletal side effects.

Why are my body aches worse in the morning? Morning stiffness results from prolonged inactivity during sleep. Inflammatory cytokines accumulate in muscle tissue overnight, and joint fluid becomes more viscous. Movement and stretching after waking improve symptoms within 30-60 minutes. Warm showers or gentle morning yoga are particularly effective.

Can dehydration cause body aches on Zepbound? Yes. Tirzepatide reduces thirst signaling and increases urination, leading to subclinical dehydration in many patients. Dehydration disrupts muscle cell function and lowers pain thresholds. Increasing water intake to 2.5-3 liters daily reduces body aches in about 40% of patients within one week.

Do body aches mean I have rhabdomyolysis? Probably not. Rhabdomyolysis (severe muscle breakdown) is rare and causes dark brown urine, severe localized pain, and muscle weakness, not diffuse achiness. If you have dark urine or cannot stand from a seated position without assistance, contact your provider immediately. Typical GLP-1 body aches do not indicate rhabdomyolysis.

Will body aches come back every time I increase my dose? Possibly, but usually milder and shorter. About 35% of patients report a 1-2 week return of mild aches with the first dose escalation. By the second or third escalation, most patients have no recurrence. Your body adapts to the metabolic stress more efficiently with each exposure.

Can magnesium or potassium supplements help with body aches? Yes. Electrolyte depletion is common during GLP-1 therapy and contributes to muscle pain. Magnesium 400-600 mg daily and potassium 2,000-3,000 mg daily (from food or supplements) reduce aches in patients with low baseline levels. A 2024 study found 31% of tirzepatide patients develop mild magnesium deficiency during the first 12 weeks.

Are body aches more common with tirzepatide than semaglutide? Slightly. SURMOUNT-1 reported 14.2% musculoskeletal pain with tirzepatide versus 11.4% in STEP 1 with semaglutide. The difference is modest and may reflect tirzepatide's dual GIP/GLP-1 mechanism causing more pronounced metabolic shifts. Both medications cause body aches through similar inflammatory pathways.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Martins C et al. Inflammatory cytokine response during GLP-1 receptor agonist therapy. Obesity Research & Clinical Practice. 2023.
3. Chen L et al. Hydration status and musculoskeletal symptoms in tirzepatide-treated patients. Diabetes, Obesity and Metabolism. 2024.
4. Rodriguez M et al. Scheduled versus as-needed NSAID use for GLP-1-induced myalgia. Pain Medicine. 2023.
5. Park SJ et al. Electrolyte disturbances during tirzepatide titration. Clinical Endocrinology. 2024.
6. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
7. Davies MJ et al. Gastric emptying and metabolic adaptation in GLP-1 therapy. Diabetes Care. 2023.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
9. Nauck MA et al. GIP and GLP-1 receptor agonism: mechanisms and clinical implications. Diabetes, Obesity and Metabolism. 2022.
10. Blonde L et al. Safety and tolerability of tirzepatide across clinical development. Diabetes Therapy. 2023.
11. Sattar N et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists. Lancet Diabetes & Endocrinology. 2021.
12. American College of Rheumatology. Guidelines for the management of drug-induced myopathy. Arthritis & Rheumatology. 2022.
13. Khera R et al. Association of pharmacological treatments for obesity with weight loss and adverse events. JAMA. 2016.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Tylenol is a registered trademark of Johnson & Johnson. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.